

1 “This document is the Accepted Manuscript version of a Published Work that appeared in
2 final form in *Toxicology and Applied Pharmacology*, copyright © 2018 Elsevier Inc after
3 peer review and technical editing by the publisher. To access the final edited and published
4 work see [https://doi: 10.1016/j.taap.2018.03.008](https://doi:10.1016/j.taap.2018.03.008).”

5
6 **THE DUAL ROLE OF MITOCHONDRIAL SUPEROXIDE IN ARSENITE**
7 **TOXICITY: signaling at the boundary between apoptotic commitment and**
8 **cytoprotection**

9 Mara Fiorani, Andrea Guidarelli, Valentina Capellacci, Liana Cerioni, Rita Crinelli and
10 Orazio Cantoni*

11 *Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino “Carlo Bo”,*
12 *61029 Urbino, Italy*

13
14 Author Email addresses:

15 mara.fiorani@uniurb.it; andrea.guidarelli@uniurb.it; valentina.capellacci@uniurb.it;
16 liana.cerioni@uniurb.it; rita.crinelli@uniurb.it; orazio.cantoni@uniurb.it

17
18 *Corresponding author: Prof. Orazio Cantoni, Dipartimento di Scienze Biomolecolari,
19 Sezione di Farmacologia e Farmacognosia, Università degli Studi di Urbino, Via S.
20 Chiara 27, 61029 Urbino (PU), Italy. Tel: +39-0722-303523; Fax: +39-0722-303521; e-
21 mail: orazio.cantoni@uniurb.it

22
23 **Abbreviations:** AA, L-ascorbic acid; BSO, DL-buthionine-[S,R]-sulfoximine; CsA,
24 cyclosporin A; DHR, dihydrorhodamine 123; DTNB, dithiobis-(2-nitrobenzoic acid);
25 EB, extracellular buffer; γ -GCS, γ -glutamylcysteine synthase; GCLC, γ -GCS catalytic
26 heavy subunit; GCLM, γ -GCS regulatory light subunit; GSH, glutathione; Keap1, Kelch-
27 like ECH-associated protein 1; MitoO₂⁻, mitochondrial superoxide; MPT, mitochondrial

28 permeability transition; NO, nitric oxide; Nrf2, nuclear factor erythroid 2 p45-related
29 factor 2; O₂⁻, superoxide; PBS, phosphate buffered solution; RD cells, respiration-
30 deficient cells.

31

32 **Abstract**

33 Arsenite toxicity is in numerous cellular systems dependent on the formation of reactive
34 oxygen and or nitrogen species. This is also true in U937 cells in which the metalloid
35 selectively promotes the formation of mitochondrial superoxide (mitoO₂⁻) rapidly converted
36 to diffusible H₂O₂. We tested the hypothesis that, under the same conditions, mitoO₂⁻ also
37 mediates the triggering of a parallel survival signaling. We found that a low concentration
38 of the metalloid causes an early activation of nuclear factor erythroid 2 p45-related factor 2
39 (Nrf2), and a downstream signaling leading to enhanced GSH biosynthesis, *via* a mechanism
40 sensitive to various treatments/strategies selectively preventing mitoO₂⁻ formation. Under
41 the same conditions, the toxic effects mediated by arsenite, leading to delayed mitochondrial
42 permeability transition (MPT)-dependent apoptosis, were also prevented. Additional studies
43 revealed remarkable similarities in the kinetics of mitoO₂⁻ formation, MPT induction, Nrf2
44 activation and GSH biosynthesis, prior to the onset of apoptosis in a small portion of the
45 cells. Importantly, mitoO₂⁻ formation, as well as the ensuing toxic events, were significantly
46 potentiated and anticipated under conditions associated with inhibition of *de novo* GSH
47 biosynthesis triggered by the metalloid through Nrf2 activation.

48 We conclude that, in the arsenite toxicity paradigm under investigation, mitoO₂⁻
49 represents the only trigger of two opposite pathways leading to activation of the Nrf2
50 signaling and/or to a MPT-dependent apoptotic death. The first pathway, through enhanced
51 GSH biosynthesis, mitigates the extent of further mitoO₂⁻ formation, thereby limiting and
52 delaying an otherwise rapid and massive apoptotic death.

53 **Keywords:** arsenite; mitochondrial superoxide; Nrf2, GSH; mitochondrial permeability
54 transition; apoptosis

56 1. Introduction

57 Arsenite is a widely diffused environmental toxicant. Epidemiological studies have
58 demonstrated that human exposure to the metalloid, mainly resulting from the ingestion of
59 contaminated drinking water, significantly increases the risk to develop various types of cancer
60 and other chronic pathologies (Flora, 2011; Jomova et al., 2011). Although various mechanisms
61 have been thus far proposed to explain the carcinogenic and toxic effects of the metalloid, in
62 particular those resulting from its direct binding to thiol residues of target molecules (Shen et al.,
63 2013; Watanabe and Hirano, 2013; Mandal, 2017), the involvement of reactive oxygen species
64 (ROS) in these events is nowadays widely accepted (Flora, 2011; Jomova et al., 2011;
65 Ellinsworth, 2015). Indeed, numerous studies have used various approaches to provide an
66 indication of ROS formation and to infer the involvement of these species in the resulting
67 lesions through the demonstration of a protective effect mediated by antioxidant
68 supplementation (Flora, 2011; Jomova et al., 2011; Rao et al., 2017).

69 Less studies have instead addressed the question of the origin and identity of the ROS
70 produced in response to arsenite, and the limited amount of information available indicates that
71 the mechanism(s) leading to superoxide ($O_2^{\cdot-}$) formation is largely dependent on the cell type
72 and treatment condition. For example, the involvement of NADPH oxidase has been reported in
73 some cell types (Smith et al., 2001; Straub et al., 2008; Flora, 2011; Li et al., 2014; Ellinsworth,
74 2015), in which the relevance of this pathway of $O_2^{\cdot-}$ production is likely dependent on the level
75 of expression of NADPH oxidase itself. Activation of this pathway may then result in
76 mitochondrial dysfunction, thereby recruiting an additional mechanism of $O_2^{\cdot-}$ formation (Li et
77 al., 2014). In this perspective, the selective activation of mitochondrial $O_2^{\cdot-}$ (mito $O_2^{\cdot-}$)
78 formation is more likely to take place in cell types poorly expressing NADPH oxidase. Evidence

79 of mitoO_2^- formation has been provided in a limited number of studies (Flora, 2011; Jomova et
80 al., 2011; Guidarelli et al., 2016a; Guidarelli et al., 2016b). Additional factors affecting the cell
81 type-dependence of the ROS response to arsenite are related to the expression of nitric oxide
82 (NO) synthase, as the diffusion-limited reaction of O_2^- with NO leads to the formation of
83 peroxynitrite, a highly reactive and toxic species (Liu et al., 2005; Jomova et al., 2011;
84 Ellinsworth, 2015). Cells not expressing NO synthase will be eventually damaged by H_2O_2 , the
85 dismutation product of O_2^- , with different sub-cellular concentrations of the oxidant expected to
86 result from mitoO_2^- formation, associated with the effect of manganese superoxide dismutase, or
87 NADPH-oxidase-derived O_2^- , associated with the action of copper/zinc superoxide dismutase.

88 These simple considerations, while representing only a small part of a more complicate
89 scenario, nevertheless emphasize the importance of learning more on the site in which ROS are
90 being generated in response to arsenite. These mechanisms necessarily impact on the identity,
91 and sub-cellular concentrations, of the downstream species produced and are also critical to
92 correctly address the study of the indirect effects of arsenite, for example at the level of gene
93 expression, induction of damage on different sub-cellular targets, apoptotic and even survival
94 signaling responses.

95 By keeping these considerations in mind, we initially characterized the effects of arsenite
96 in promonocytic U937 cells to understand more on the antileukemic and toxic effects of the
97 metalloid (Guidarelli et al., 2015; Guidarelli et al., 2016a). Our interest was also stimulated by
98 the observation that in these cells low concentrations of arsenite (e.g., 2.5 μM) selectively
99 promote mitoO_2^- formation, in the absence of detectable effects mediated by NADPH oxidase
100 (Guidarelli et al., 2016b). This notion was established using various approaches and
101 significantly greater concentrations of the metalloid were necessary in order to promote
102 detectable NADPH oxidase activation. As an example, 10 μM arsenite caused in respiration-
103 deficient U937 cells (which fail to produce mitoO_2^- in response to 2.5 μM arsenite) a NADPH

104 oxidase inhibitor-sensitive DHR fluorescence response similar to that mediated by 2.5 μ M
105 arsenite in respiration-proficient cells.

106 Thus, the metalloid caused the selective formation of mitoO_2^- and we were indeed able to
107 selectively suppress this response with rotenone, an inhibitor of complex I (Degli Esposti, 1998),
108 or using the same cells manipulated to induce respiratory deficiency (Guidarelli et al., 2016a;
109 Guidarelli et al., 2016b). It is important to remind that U937 cells are highly glycolytic, and
110 therefore maintain high ATP levels, and remain viable, under conditions of impaired
111 function/activity of the mitochondrial respiratory chain (Brand and Hermfisse, 1997).

112 An additional advantage of the specific cell type employed is related to the expression of
113 high affinity transporters of L-ascorbic acid (AA) in both the plasma and mitochondrial
114 membranes (Azzolini et al., 2013; Fiorani et al., 2015a; Fiorani et al., 2015b), a condition
115 favoring the selective accumulation of AA in mitochondria after exposure to low extracellular
116 concentrations of the vitamin (Azzolini et al., 2013; Fiorani et al., 2015a). Under these
117 conditions, intramitochondrial AA very rapidly and effectively scavenged mitoO_2^- (Guidarelli et
118 al., 2016a). Using these treatments, we were able to demonstrate a selective suppression of ROS
119 formation mediated by arsenite, and hence establish the pivotal role of mitoO_2^- and its down-
120 stream products in the induction of the deleterious effects elicited by the metalloid (Guidarelli et
121 al., 2017).

122 The specific characteristics of the U937 cell clone used in our laboratory can also be used
123 to address additional questions, for example related to the role of mitoO_2^- in the activation of
124 specific cytoprotective signaling pathways, as the one connected to the nuclear factor (erythroid-
125 2 related) factor 2 (Nrf2) (Abdul-Aziz et al., 2015; Tebay et al., 2015; Hourihan et al., 2016).

126 Oxidative and electrophilic stress are associated with an initial dissociation of Nrf2 from
127 Kelch-like ECH-associated protein 1 (Keap1) and its subsequent translocation and accumulation
128 in the nucleus (Tebay et al., 2015; Hourihan et al., 2016). The transcription factor promotes
129 enhanced expression of an array of antioxidant enzymes (Abdul-Aziz et al., 2015; Tebay et al.,

130 2015; Hourihan et al., 2016), which include γ -glutamylcysteine synthase (γ -GCS, (Abdul-Aziz
131 et al., 2015; Tebay et al., 2015)), the rate-limiting enzyme of GSH biosynthesis (Griffith and
132 Mulcahy, 1999; Franklin et al., 2009), comprising a catalytic heavy subunit, (GCLC) and a
133 regulatory light subunit (GCLM). Activation of these pathways leading to enhanced GSH
134 biosynthesis is of extreme importance for providing cytoprotection in a variety of toxicity
135 paradigms (Flora, 2011; Hou et al., 2014; Forman, 2016).

136 It has been reported that arsenite induces the dissociation of Nrf2 from Keap 1 (Pi et al.,
137 2003; Lau et al., 2013). Although some studies claimed a role for a direct binding of arsenite to
138 either Keap 1 or Nrf2 (He and Ma, 2009; He and Ma, 2010), Nrf2 activation is often reported to
139 depend also on ROS formation. This notion is normally established by studies showing that
140 Nrf2 activation is sensitive to very high concentrations of N-acetylcysteine (Ray et al., 2015;
141 Rossler and Thiel, 2017), or other antioxidants (Choudhury et al., 2016; Gong et al., 2016), with
142 a need of a more selective approach linking the cytoprotective signaling to the specific sources
143 from which ROS are released by the metalloid.

144 The study of the effect of mitoO_2^- in the Nrf2 signaling, using selective strategies to
145 prevent the formation of these species, would therefore allow a more clear definition of their
146 role in Nrf2 activation. The approach of selectively targeting mitoO_2^- to understand its role in
147 a cytoprotective signaling appears even more important under conditions in which the same
148 species is also involved in the triggering of events leading to apoptosis.

149 In this perspective, the respective timing of these responses appears of particular
150 importance to determine the dynamics regulating critical steps of the final decision of the cells
151 to survive or die. This information is necessary to further our knowledge, thus far limited to the
152 demonstration that cells overexpressing Nrf2 (or downstream effectors) are particularly resistant
153 to arsenite, and that down-regulation of these systems remarkably enhances the sensitivity of the
154 cells to the metalloid (Wang et al., 2007; Jiang et al., 2009; Yang et al., 2012; Son et al., 2015;
155 Chen et al., 2017).

156 The present study was designed to determine the role of mitoO_2^- released in response to a
157 low concentration (i.e., promoting delayed apoptosis in a limited portion of cells) of arsenite in
158 the induction/activation of Nrf2 (Pi et al., 2003; Li et al., 2013). Our results indicate that
159 mitoO_2^- is responsible for the induction of two opposite pathways associated with the early
160 activation of the Nrf2 signaling and the delayed induction of mitochondrial permeability-
161 transition (MPT)-dependent apoptosis. The first pathway significantly blunted and delayed the
162 MPT-dependent apoptosis induced by the metalloid through a mechanism associated with
163 enhanced GSH biosynthesis and inhibition of excessive mitoO_2^- formation.
164

165 **2. Materials and Methods**

166 *2.1. Chemicals.*

167 Sodium arsenite, AA, rotenone, diphenyleneiodonium (DPI), apocynin (Apo), phorbol-12-
168 myristate-13-acetate (PMA), DL-buthionine-[S,R]-sulfoximine (BSO), Hoechst 33342, GSH,
169 dithiobis-(2-nitrobenzoic acid), (DTNB) as well most of the reagent-grade chemicals were
170 purchased from Sigma-Aldrich (Milan, Italy). Cyclosporin A (CsA) was from Novartis (Bern,
171 Switzerland). Dihydrorhodamine 123 (DHR) and MitoTracker Red CMXRos were purchased from
172 Molecular Probes (Leiden, The Netherlands). Acetonitrile was acquired from Carlo Erba (Carlo
173 Erba Reagenti, Milan, Italy).

174 *2.2. Cell culture and treatment conditions.*

175 U937 human myeloid leukemia cells were cultured in suspension in RPMI 1640 medium
176 (Sigma-Aldrich, Milan, Italy) supplemented with 10% fetal bovine serum (Euroclone, Celbio
177 Biotecnologie, Milan, Italy), penicillin (100 units/ml) and streptomycin (100 µg/ml) (Euroclone),
178 at 37 °C in T-75 tissue culture flasks (Corning Inc., Corning, NY, USA) gassed with an
179 atmosphere of 95% air-5% CO₂. U937 cells were made respiration-deficient (RD cells) as
180 indicated in (Guidarelli et al., 2016b). Sodium arsenite was prepared as a 1 mM stock solution in
181 saline A (140 mM NaCl, 5 mM KCl, 4 mM NaHCO₃, and 5 mM glucose; pH 7.4) and stored at
182 4°C. Cells (1 x 10⁵ cells/ml) were exposed to arsenite in complete RPMI 1640 culture medium, as
183 reported in the legends to the figures. A 10 mM AA stock solution was prepared in extracellular
184 buffer (EB, 15 mM Hepes, 135 mM NaCl, 5 mM KCl, 1.8 mM CaCl₂, 0.8 mM MgCl₂, pH 7.4)
185 immediately before use. Cells (1 x 10⁶ cells/ml) were treated with AA in EB supplemented with
186 0.1 mM dithiothreitol for 15 min at 37°C. Stability of AA under these conditions was assessed by
187 monitoring the absorbance at 267 nm for 15 min ($\epsilon_{267} = 14,600 \text{ M}^{-1}\text{cm}^{-1}$).

188 *2.3. Western Immunoblotting analysis.*

189 After treatments, the cells were washed with phosphate buffer saline (PBS, 136 mM NaCl, 10
190 mM Na₂HPO₄, 1.5 mM KH₂PO₄, 3 mM KCl; pH 7.4) and lysed by sonication in a sodium dodecyl

191 sulphate (SDS) buffer containing 50 mM Tris-HCl pH 8.0, 2% (w/v) SDS, 10 mM N-
192 ethylmaleimide, supplemented with a commercial cocktail of protease inhibitors (Roche
193 Diagnostic, Monza, Italy). Lysates were boiled for 3 min and then centrifuged for 5 min at 12000 x
194 g. The protein content was determined according to Lowry (Lowry et al., 1951), using bovine
195 albumin as standard. Proteins were separated on 8% SDS polyacrylamide gels, transferred onto
196 nitrocellulose membrane and probed with the following antibodies: anti Nrf2 (D1Z9C, Cell
197 Signaling Technology, Leiden, The Netherlands), anti GCLC (PA5-16581, ThermoFisher
198 Scientific, Monza, Italy) and anti actin (A2066, Sigma-Aldrich). Immunoreactive bands were
199 detected using horseradish peroxidase-conjugated secondary antibody (BioRad, Milan, Italy).
200 Peroxidase activity was detected with the enhanced chemiluminescence detection method
201 (WesternBright ECL, Advasta, Roma, Italy).

202 *2.4. Measurement of total, protein and non-protein thiols.*

203 Total, protein and non-protein thiols were colorimetrically quantified by DTNB (Ellman,
204 1959). After treatments, the cells (4×10^6) were washed three times with PBS and the pellets
205 resulting from the last centrifugation were suspended in lysis buffer (0.1% Triton X-100, 0.1 M,
206 Na_2HPO_4 , 5 mM EDTA, pH 7.5) and incubated for 10 min at ice-bath temperature. The total thiol
207 content was measured spectrophotometrically, at 412 nm, using DTNB ($\epsilon_{412} = 13,600 \text{ M}^{-1} \cdot \text{cm}^{-1}$).
208 For the assessment of protein thiols, the lysates were centrifuged on 10,000 MWCO centrifugal
209 filters AMICON® ULTRA 4 (Millipore, Milan, Italy) and the concentrated protein (with
210 molecular weight ≥ 10 kDa) fractions were analyzed as indicated above. Non-protein thiol content
211 was determined in the acid soluble fraction obtained from the same lysates, as described by
212 Beutler (Beutler, 1984).

213 *2.5. Measurement of GSH content by High Performance Liquid Chromatography.*

214 The cells (1×10^6) were suspended in 100 μl of lysis buffer, vortexed and kept for 10 min on
215 an ice bath. Thereafter, 15 μl of 0.1 N HCl and 140 μl of precipitating solution (0.2 M-glacial
216 meta-phosphoric acid, 5 mM sodium EDTA, 5 M NaCl) were added to the samples. After

217 centrifugation, the supernatants were collected and kept at -20° C until the HPLC analyses. Just
218 before analysis, 60 μ l of the acid extract were supplemented with 15 μ l of 0.3 M Na_2HPO_4 and 15
219 μ l of a solution containing 20 mg of DTNB in 100 ml of sodium citrate (1% w/v). The mixture
220 was stirred for 1 min at room temperature and, after 5 min, filtered through 0.22 μ m pore micro-
221 filters. The resulting samples were finally analyzed for their GSH content by an HPLC assay
222 (Brundu et al., 2016), using a 15 cm x 4.6 mm, 5 μ m Supelco Discovery® C18 column (Supelco,
223 Bellefonte, PA). The UV absorption was detected at 330 nm. The injection volume was 20 μ l. The
224 retention time of GSH was approximately 15.7 min.

225 *2.6. DHR fluorescence assay.*

226 The cells were incubated for 30 min with 10 μ M DHR prior to the end of the incubation with
227 arsenite, washed three times and analysed with a fluorescence microscope. Fluorescence images
228 were captured with a BX-51 microscope (Olympus, Milan, Italy), equipped with a SPOT-RT
229 camera unit (Diagnostic Instruments, Delta Sistemi, Rome, Italy) using an Olympus LC Ach 40
230 x/0.55 objective lens. The excitation and emission wavelengths were 488 and 515 nm with a 5-nm
231 slit width for both emission and excitation. Images were collected with exposure times of 100-400
232 ms, digitally acquired and processed for fluorescence determination at the single cell level on a
233 personal computer using J-Image software. Mean fluorescence values were determined by
234 averaging the fluorescence values of at least 50 cells/treatment condition/experiment.

235 *2.7. Measurement of mitochondrial membrane potential.*

236 The cells were incubated for 30 min with 50 nM MitoTracker Red CMXRos prior to the
237 end of the incubation with arsenite, washed three times and analyzed with a fluorescence
238 microscope. The resulting images were taken and processed as described above. The excitation
239 and emission wavelengths were 545 and 610 nm, respectively, with a 5-nm slit width for both
240 emission and excitation. Mean fluorescence values were determined by averaging the
241 fluorescence values of at least 50 cells/treatment condition/experiment.

242 *2.8. Immunofluorescence analysis.*

243 After treatments, the cells were suspended in 2 ml of saline A and incubated for 30 min in
244 35-mm tissue culture dishes containing an uncoated coverslip. Under these conditions, cells
245 rapidly attach to the coverslip. In some experiments the cells were incubated for 5 min with the
246 cell-permeable DNA dye (Hoechst 33342, 10 μ M) prior to the end of incubation to stain the
247 nucleus. The cells were then fixed for 1 min with 95% ethanol/5% acetic acid, washed with PBS
248 and blocked in PBS containing bovine serum albumin (2% w/v) (30 min at room temperature).
249 The cells were subsequently incubated with rabbit polyclonal anti-P47^{phox} (sc-17844) (1:100 in
250 PBS supplemented with 2% bovine serum albumin; Santa Cruz Biotechnology Inc. USA), rabbit
251 polyclonal anti-Nrf2 (1:50 in PBS containing 2% bovine serum albumin; Santa Cruz
252 Biotechnology) or monoclonal anti-cytochrome c antibody (1:100 in PBS containing 2% bovine
253 serum albumin; Santa Cruz Biotechnology) stored for 18 h at 4° C, washed and then incubated for
254 3 h in the dark with fluorescein isothiocyanate (Santa Cruz Biotechnology)-conjugated secondary
255 antibody diluted 1:100 in PBS. Stained cells were captured with a fluorescence microscope and
256 the resulting images were processed for fluorescence determination as described above.

257 *2.9. Fluorogenic caspase 3 assay.*

258 Caspase 3-like activity was monitored as described in Guidarelli *et al.* (Guidarelli et al.,
259 2005). Briefly, the cells were lysed and aliquots of the extract (30 μ g proteins) were incubated
260 with 12 μ M Ac-DEVD-AMC, at 30 °C. Caspase 3-like activity was determined fluorometrically,
261 with excitation at 360 nm and emission at 460 nm, by quantifying the release of
262 aminomethylcoumarin (AMC) from cleaved caspase 3 substrate (Ac-DEVD-AMC).

263 *2.10. Analysis of apoptosis with the Hoechst 33342 assay.*

264 After treatments, the cells were incubated for 5 min with 10 μ M Hoechst 33342 and then
265 analysed with a fluorescence microscope to assess their nuclear morphology (chromatin
266 condensation and fragmentation). Cells with homogeneously stained nuclei were considered
267 viable.

268 *2.11. Statistical analysis.*

269 The results are expressed as means \pm SD. Statistical differences were analyzed by one-way
270 ANOVA followed by Dunnett's test for multiple comparison or two-way ANOVA followed by
271 Bonferroni's test for multiple comparison. A value of $P < 0.05$ was considered significant.

272

273 **3. Results**

274 *3.1. Time-dependence of the activation of the Nrf2 signalling pathway.*

275 Logarithmically growing U937 cells were exposed for increasing time intervals to 2.5 μ M
276 arsenite and then processed for Western blot analysis of Nrf2 protein expression. As shown in
277 Fig. 1A, very low levels of Nrf2 were detected in whole lysates from untreated cells during the 16
278 h of incubation. Expression of the transcription factor was instead remarkably enhanced in cells
279 exposed for 4 h to arsenite, with a progressive decline being observed at later times of incubation.
280 Enhanced Nrf2 expression is normally associated with its nuclear translocation and the ensuing
281 transactivation of target genes (Abdul-Aziz et al., 2015; Tebay et al., 2015; Hourihan et al., 2016).
282 Consistently, immunofluorescence studies provided evidence of Nrf2 nuclear translocation after a
283 6 h exposure to arsenite (Fig. 1B). In addition, expression of GCLC was significantly increased 4
284 h after addition of arsenite. The maximal increase in GCLC expression was detected at 6 h and
285 these levels were maintained throughout the entire period of exposure to the metalloid. These
286 results are indicative of a positive effect of arsenite on GSH biosynthesis. A significant increase
287 in cellular GSH content was indeed detected in cells exposed for 4 h to the metalloid, with a
288 plateau reached at the 8 h time point (Fig. 1C).

289 A final set of experiments was performed in cells exposed for 16 h to 2.5 μ M arsenite to obtain an
290 indication on the cellular sulphhydryl status of the cells. As shown in Fig. 1D, this treatment
291 significantly enhanced the total thiol content of the cells, with hardly any effect detected on
292 protein thiols. In fact, the increased thiol response was entirely attributable to the non-protein
293 thiol pool (95% of which is represented by GSH, (Meister and Anderson, 1983)).

294 These results indicate that, under the conditions employed, arsenite promotes time-dependent Nrf2
295 activation and enhanced GCLC expression associated with increased GSH biosynthesis.

296 *3.2. The Nrf2 signaling pathway is activated by mitochondrial superoxide.*

297 DHR is a general fluorescence probe responsive to extramitochondrial $O_2^{\cdot-}$, hydrogen
298 peroxide (Gomes et al., 2005) as well as reactive nitrogen species (Kooy et al., 1994), which

299 however are not produced under the experimental conditions employed in these studies (Guidarelli
300 et al., 2016a). Fig. 2A shows the time-dependence of the DHR-fluorescence response induced by
301 2.5 μM arsenite that, based on the sensitivity to rotenone, AA or the respiration-deficient
302 phenotype appears entirely mediated by mitoO_2^- (Fig. 2A). These results are in keeping with our
303 previous findings obtained in cells exposed to arsenite for 16 h (Guidarelli et al., 2016a; Guidarelli
304 et al., 2017). Rotenone, or AA, also suppressed the enhanced expression of both Nrf2 and GCLC
305 (Fig. 2B), and the increased GSH biosynthesis (Fig. 2C), detected respectively 6 and 8 h after
306 addition of 2.5 μM arsenite. In addition, the metalloid produced hardly any effect on RD cell GSH
307 (Fig. 2C), thereby implying the absence of an upstream Nrf2 signaling in cells unable to generate
308 mitoO_2^- in response to arsenite (Fig. 2A).

309 These results indicate that mitoO_2^- is the species responsible for the arsenite-dependent activation
310 of the Nrf2/GCLC signaling leading to increased GSH biosynthesis. Complete suppression of this
311 signaling response by treatments/manipulations abolishing mitoO_2^- formation argues against the
312 involvement of additional mechanisms leading to activation of the transcription factor.

313 *3.3. The increased GSH biosynthesis reduces mitochondrial superoxide formation.*

314 We tested the impact of enhanced GSH synthesis in arsenite toxicity with the use of a low
315 concentration of BSO, an inhibitor of γ -GCS (Meister and Anderson, 1983). As indicated in Fig.
316 3A, 2.5 μM BSO promoted a time-dependent decrease in cellular GSH, detectable after 4 h and
317 reaching an about 30% decrease at 16 h. It was interesting to observe that a superimposable curve
318 was obtained using cells supplemented with both BSO and arsenite, thereby implying that BSO
319 prevents the enhanced GSH biosynthesis induced by the metalloid. The results illustrated in Fig.
320 3B indicate that BSO, under the same conditions, significantly increased the extent of the time-
321 dependent DHR-fluorescence response elicited by arsenite. BSO instead failed to produce effects
322 in the absence of additional treatments. The DHR-fluorescence response detected 8 and 16 h after
323 addition of arsenite was suppressed by rotenone, the respiration-deficient phenotype or AA,
324 regardless of whether induced by the metalloid alone (Fig. 2A) or associated with BSO (Fig. 3C).

325 These results suggest that inhibition of the GSH response significantly enhances the mitochondrial
326 mechanisms leading to $O_2^{\cdot-}$ formation, with no evidence for a recruitment of additional
327 mechanisms. The possibility of an activation of NADPH oxidase was nevertheless tested. We
328 recently demonstrated that Apo and DPI, two different NADPH inhibitors (Brandes et al., 2014),
329 fail to affect the DHR-fluorescence response evoked by arsenite in the absence of other treatments
330 (Guidarelli et al., 2016b). The results illustrated in Fig. 3C indicate that similar results are
331 obtained after combined exposure to arsenite and BSO. Moreover, there was no evidence of
332 activation of NADPH oxidase, as measured by immunocytochemical detection of its membrane
333 translocation, in cells exposed for 16 h to arsenite alone, as we previously demonstrated
334 (Guidarelli et al., 2016b), or associated with BSO (Fig. 3Da and b). PMA was used as positive
335 control to promote Apo-, or DPI-, sensitive activation of NADPH oxidase (Fig. 3Dc-e) and DHR
336 fluorescence (Fig. 3Df). The results presented in this section indicate that the increased GSH
337 biosynthesis induced by arsenite is functionally-linked to events limiting $mitoO_2^{\cdot-}$ formation.

338 *3.4. The increased GSH biosynthesis mitigates mitochondrial dysfunction.*

339 We have previously reported that arsenite causes U937 cell death *via* a mechanism mediated
340 by the formation of $mitoO_2^{\cdot-}$, leading to loss of mitochondrial membrane potential and MPT, and
341 to the ensuing triggering of the mitochondrial pathway of apoptosis (Guidarelli et al., 2015;
342 Guidarelli et al., 2016a). We therefore tested whether BSO, by anticipating and increasing the rate
343 of $O_2^{\cdot-}$ formation, also promotes similar effects on the apoptotic cascade. As indicated in Fig. 4A,
344 arsenite elicited a time-dependent mitochondrial depolarization and this response was significantly
345 increased by concomitant exposure to BSO. Furthermore, loss of mitochondrial membrane
346 potential detected at 16 h was sensitive to treatments preventing $mitoO_2^{\cdot-}$ formation and to the
347 MPT inhibitor CsA, regardless of whether induced by the metalloid alone (Guidarelli et al., 2015;
348 Guidarelli et al., 2016a) or associated with BSO (Fig. 4B). These results therefore suggest that
349 BSO increases the sensitivity of the cells to MPT induced by arsenite. The CsA-sensitive release
350 of cytochrome c was next assessed to further support the notion that the GSH response delays and

351 mitigates the onset of MPT in cells exposed to arsenite. For this purpose, we employed an
352 immunocytochemical approach allowing detection of a punctuate fluorescence in untreated cells,
353 consistently with the mitochondrial localization of cytochrome c. MPT is associated with a loss of
354 the punctuate fluorescence as a consequence of the dilution of cytochrome c released by the
355 mitochondria in the cytosol. The use of this approach allowed us to calculate the number of cells
356 presenting evidence of mitochondrial loss of cytochrome c, indicative of MPT, in response to
357 various treatments and conditions. The results summarized in Fig. 4C indicate that a 6 h exposure
358 to arsenite promotes cytochrome c release in a very small proportion of the cells, that dramatically
359 increased upon supplementation of BSO, which instead failed to produce effects in the absence of
360 the metalloid. As previously observed in experiments measuring loss of mitochondrial membrane
361 potential, the effects mediated by arsenite/BSO in terms of mitochondrial loss of cytochrome c
362 were sensitive to CsA, rotenone, the respiration-deficient phenotype or AA. These results
363 therefore emphasize the relevance of the GSH response elicited by arsenite in the triggering of
364 events leading to prevention of mitochondrial dysfunction. Inhibition of *de novo* GSH
365 biosynthesis indeed anticipates and increases mitochondrial depolarization and MPT.

366 3.5. *The increased GSH biosynthesis delays and mitigates apoptosis.*

367 We performed experiments to determine whether the increased rate of mitoO₂⁻ formation,
368 resulting from inhibition of the GSH response, also anticipates and increases the arsenite-
369 dependent apoptosis. In these experiments, the cells were exposed for 6 or 16 h to arsenite,
370 conditions respectively associated with no or barely detectable levels of caspase 3 activation (Fig.
371 5A). As previously reported, significant activation of caspase 3 is instead detected after 16-48 h
372 (Guidarelli et al., 2017). Supplementation of BSO resulted in remarkably increased caspase 3
373 activity, appreciable even at the shortest time of incubation. Furthermore, under both conditions,
374 activation of caspase 3 was sensitive to CsA, rotenone, the respiration-deficient phenotype or AA.
375 These results therefore provide evidence for a significant anticipation of the processes leading to
376 activation of caspase 3, critically involved in the mitochondrial pathway of apoptosis (Kurokawa

377 and Kornbluth, 2009; Fiandalo and Kyprianou, 2012). Further analyses measuring chromatin
378 condensation/fragmentation indeed revealed that 2.5 μ M arsenite promotes an apoptotic response,
379 barely detectable at 24 h and increasing thereafter (Fig. 5B). About 15% of the cells were
380 apoptotic at 48 h, as we also recently reported (Guidarelli et al., 2015; Guidarelli et al., 2016a).
381 Interestingly, BSO significantly enhanced, and remarkably anticipated, the apoptotic response
382 mediated by the metalloid. CsA, rotenone, the respiration-deficient phenotype and AA prevented
383 apoptosis in cells exposed to the metalloid alone (Guidarelli et al., 2016a; Guidarelli et al., 2016b)
384 or associated with BSO (inset to Fig. 5B). The last series of experiments was performed using
385 cells exposed for 16 h to arsenite in the absence or presence of increasing concentrations of BSO.
386 In keeping with the results illustrated in Fig. 3A, an identical progressive decline in cellular GSH
387 levels was observed under both conditions (Fig. 5C). Furthermore, BSO caused a dose-dependent
388 induction of apoptosis in cells supplemented with arsenite, with hardly any effect detected after
389 exposure to the metalloid or BSO alone (Fig. 5D). These results provide compelling evidence for
390 the relevance of the GSH response, elicited by arsenite *via* a mechanism entirely mediated by
391 mitoO_2^- , in the triggering of events counteracting excessive mitoO_2^- formation and the ensuing
392 mitochondrial dysfunction and apoptosis.

393

394 4. Discussion

395 Our previous studies showed that arsenite exposure of U937 cells leads to the selective and
396 unique formation of mitoO_2^- (Guidarelli et al., 2016a; Guidarelli et al., 2016b; Guidarelli et al.,
397 2017), an event responsible for the triggering of downstream events leading to mitochondrial
398 dysfunction and apoptosis (Guidarelli et al., 2016a; Guidarelli et al., 2016b). This cause-effect
399 relationship was not established with the use of high concentrations of non-specific
400 antioxidants/radical scavengers but, rather, with the use of treatment/manipulations selectively
401 blunting mitoO_2^- formation. In particular, the formation of this species was inhibited either
402 chemically, i.e. with rotenone through the suppression of complex I activity (Degli Esposti, 1998),
403 or with the use of cells manipulated to induce respiratory-chain deficiency. Under these different
404 conditions, prevention of mitoO_2^- formation was invariably associated with suppression of
405 mitochondrial dysfunction and cytotoxicity. An additional approach to reach the same conclusion
406 was based on the observation that pre-exposure to a low concentration of AA (10 μM) results in
407 the same protective effects. It is important to emphasize that our previous studies demonstrated
408 that mitochondrial AA effectively and rapidly scavenge mitoO_2^- generated in response to arsenite
409 (Guidarelli et al., 2015; Guidarelli et al., 2016a), with hardly any effect mediated by cytosolic AA.

410 This premise, while recapitulating critical information relevant for the experimental design of
411 the present study, emphasises the notion that mitoO_2^- is a critical player of the arsenite-dependent
412 apoptotic response under investigation. Our results are indicative of a very little -if any-
413 contribution of other mechanisms, for example related to the direct binding of the metalloid to
414 protein and non-protein thiols (Shen et al., 2013; Watanabe and Hirano, 2013).

415 The first question addressed concerns the role of this species, and its downstream products, in
416 the triggering of the Nrf2 cytoprotective signalling. We therefore used the same approach
417 outlined above, however introducing a focus on the timing of the events under investigation. We
418 initially showed that the time-dependence of Nrf2 activation is compatible with the kinetics of
419 mitoO_2^- formation. A cause-effect relationship between these events was then established with the

420 demonstration that Nrf2 expression is abolished by treatment/conditions suppressing mitoO₂⁻
421 formation.

422 It is very well known that Nrf2 activation is associated with the expression of various
423 cytoprotective genes (Abdul-Aziz et al., 2015; Tebay et al., 2015; Hourihan et al., 2016). We
424 focused our attention on GCLC and found that its time-dependent increased expression, and the
425 resulting enhanced GSH biosynthesis, were also kinetically compatible with the upstream role of
426 mitoO₂⁻ and the ensuing Nrf2 activation. Not surprisingly, treatments blunting Nrf2 activation
427 through inhibition of mitoO₂⁻ formation also abolished the increased GCLC expression and GSH
428 biosynthesis.

429 The results thus far discussed allow a first conclusion, possibly relevant in different cellular
430 systems in which arsenite selectively promotes the formation of mitoO₂⁻. This species cannot exit
431 mitochondria and is in fact rapidly dismutated by MnSOD to diffusible H₂O₂ (Hamanaka and
432 Chandel, 2010; Kudryavtseva et al., 2016). In this direction we recently showed that, under the
433 same conditions employed in this study, arsenite-derived H₂O₂ produces distal effects, as DNA
434 strand scissions and modulation of gene expression (Guidarelli et al., 2017). Hence, the above
435 results are consistent with the notion that mitoO₂⁻, *via* the resulting H₂O₂, is the only species
436 involved in Nrf2 expression/activation, and in the ensuing GSH response. This consideration
437 apparently rules out the possible contribution of other mechanisms, as the direct binding of arsenic
438 to Nrf2 itself, or Keap1, previously described in other systems, in which however the source of the
439 radical species produced were not determined (He and Ma, 2009; He and Ma, 2010; Lau et al.,
440 2013).

441 A more general conclusion from our results is instead that mitoO₂⁻ plays a pivotal role in the
442 response of the cells to arsenite, as it critically regulates the triggering of both toxicity and
443 cytoprotective mechanisms. Future studies should determine whether the same is true for
444 NADPH-oxidase derived O₂⁻ and whether the same relationship is eventually maintained under
445 conditions in which both mechanisms are sequentially recruited. This notion will be addressed in

446 the respiration-deficient cells used in this study, that require about 4 time greater concentrations of
447 arsenite to significantly activate NADPH oxidase (Guidarelli *et al.*, 2016b).

448 An additional consideration we can make is on the relationships existing between the rate of
449 $\text{mitoO}_2^-/\text{H}_2\text{O}_2$ formation and the increased GSH biosynthesis. It has been proposed that binding of
450 arsenic to GSH leads to formation of a conjugate extruded by the cells *via* multidrug transporters,
451 an event resulting in GSH depletion and enforcing ROS formation (Leslie, 2012; Watanabe and
452 Hirano, 2013). Although the formation of the arsenic/GSH complex, and the consequent decline
453 in GSH content, would be masked by the enhanced GSH biosynthesis, we nevertheless consider
454 poorly relevant its occurrence in the toxicity paradigm under investigation, since the GSH levels
455 observed after inhibition of mitoO_2^- formation were identical to those detected in untreated cells.
456 Our conclusion is therefore that $\text{mitoO}_2^-/\text{H}_2\text{O}_2$ formation is not the consequence of GSH depletion
457 but rather a cause, eventually concealed by the Nrf2 signalling response. Another point we can
458 make is that, in the toxicity paradigm under investigation, the contribution of detoxification
459 mechanisms based on the formation of GSH-trivalent arsenic complexes (Leslie, 2012; Watanabe
460 and Hirano, 2013) is poor, or negligible.

461 The second major question addressed was on the significance of the Nrf2/GCLC/GSH
462 response, under the same conditions in which the metalloid triggers these events, and the
463 mitochondrial pathway of apoptosis, in response to the same mitoO_2^- -dependent signalling. This
464 question cannot find an explanation on previous findings obtained using cells with down-regulated
465 Nrf2 (or GCLC) expression, as obtained using siRNA technologies or KO mice (Jiang *et al.*, 2009;
466 Yang *et al.*, 2012; Yang *et al.*, 2015), or using approaches (e.g., BSO prior to treatment with
467 arsenite) leading to an initial decreased GSH pool (Meister and Anderson, 1983). All these
468 conditions are indeed associated with an impaired defence machinery and with an acquired
469 susceptibility to arsenite toxicity, which can obviously become apparent regardless of the source
470 of ROS involved.

471 The question we asked is more specifically linked to the condition of acute arsenite exposure
472 associated with the ongoing toxicity and protective signalling pathway triggered by mitoO_2^- . Our
473 kinetic studies established that the Nrf2/GCLC/GSH pathway is characterised by a rapid
474 occurrence, as maximally activated within the first 6-8 h of exposure to the metalloid.
475 Mitochondrial dysfunction is also detected under the same conditions, but then further increases in
476 the subsequent 8 h to finally promote delayed apoptotic DNA fragmentation, detected after 48 h in
477 about 15% of the cells. We were interested to determine the specific impact of the
478 Nrf2/GCLC/GSH pathway in the timing/extent of the above responses.

479 In order to approach this issue, we first established that a low concentration of BSO, 2.5 μM ,
480 suppresses the GSH response to then demonstrate that this manipulation significantly increased
481 the rate of ROS formation induced by arsenite. Interestingly, this event was entirely mediated by
482 the increased mitoO_2^- formation, since completely suppressed by rotenone, the respiration-
483 deficient phenotype or AA. In addition, we also ruled out the possibility of a recruitment of other
484 mechanisms leading to O_2^- formation, as the activation of NADPH oxidase.

485 These results therefore suggest that the triggering of the GSH response mitigates the extent of
486 time-dependent mitoO_2^- release. Although more studies should specifically address this issue, it
487 appears that mitoO_2^- initially produced by arsenite triggers the GSH response to down-modulate
488 further mitoO_2^- release. In this perspective, the increased GSH biosynthesis, which only takes
489 place in the cytosol, should lead to increased mitochondrial accumulation of GSH, an established
490 and well-characterised process (Ribas et al., 2014; Calabrese et al., 2017). Mitochondrial GSH
491 would then promote its effects by reducing mitoO_2^- formation in the mitochondrial respiratory
492 chain and supporting reactions leading to prevention of mitochondrial damage or to detoxification
493 of H_2O_2 (Ribas et al., 2014; Calabrese et al., 2017).

494 A final observation from this study was that the increased rate of mitoO_2^- formation
495 associated with prevention of the GSH response is followed by a dramatic anticipation of
496 mitochondrial dysfunction and downstream events leading to apoptosis.

497 In conclusion, our results indicate that a low concentration of arsenite induces in U937 cells
498 a time-dependent mitoO_2^- formation leading to delayed MPT-dependent apoptosis. Under the
499 same treatment conditions, mitoO_2^- -derived H_2O_2 diffuses to extramitochondrial compartments,
500 thereby promoting early activation of the Nrf2/GCLC/GSH signalling. Enhanced GSH
501 biosynthesis is then associated with inhibition of excessive mitoO_2^- formation, with an ensuing
502 decreased and delayed mitochondrial dysfunction and apoptosis. Suppression of this signalling is
503 indeed invariably associated with remarkably accelerated and enhanced rates of events leading to
504 MPT-dependent apoptosis.
505

506 **Conflict of interest statement**

507 There are no conflicts of interest.

508

509 **Transparency Document**

510 The transparency document associated with this article can be found in the online submission.

511

512

513 **Funding**

514 This work was supported by Ministero dell'Università e della Ricerca Scientifica e Tecnologica,

515 Programmi di Ricerca Scientifica di Rilevante Interesse Nazionale, 2015, [Grant number:

516 2015MJBEM2-003. O.C.].

517

518

519 **References**

- 520
- 521 Abdul-Aziz, A., MacEwan, D.J., Bowles, K.M., Rushworth, S.A., 2015. Oxidative stress
522 responses and NRF2 in human leukaemia. *Oxid. Med. Cell. Longev.* 2015, 454659.
- 523 Azzolini, C., Fiorani, M., Cerioni, L., Guidarelli, A., Cantoni, O., 2013. Sodium-dependent
524 transport of ascorbic acid in U937 cell mitochondria. *IUBMB Life* 65, 149-153.
- 525 Beutler, E., 1984. *Red cell metabolism: a manual of biochemical methods.* Grune & Stratton, New
526 York.
- 527 Brand, K.A., Hermfisse, U., 1997. Aerobic glycolysis by proliferating cells: a protective strategy
528 against reactive oxygen species. *FASEB J.* 11, 388-395.
- 529 Brandes, R.P., Weissmann, N., Schroder, K., 2014. Nox family NADPH oxidases: Molecular
530 mechanisms of activation. *Free Radic. Biol. Med.* 76, 208-226.
- 531 Brundu, S., Palma, L., Picceri, G.G., Ligi, D., Orlandi, C., Galluzzi, L., Chiarantini, L.,
532 Casabianca, A., Schiavano, G.F., Santi, M., Mannello, F., Green, K., Smietana, M.,
533 Magnani, M., Fraternali, A., 2016. Glutathione Depletion Is Linked with Th2 Polarization
534 in Mice with a Retrovirus-Induced Immunodeficiency Syndrome, Murine AIDS: Role of
535 Proglutathione Molecules as Immunotherapeutics. *J. Virol.* 90, 7118-7130.
- 536 Calabrese, G., Morgan, B., Riemer, J., 2017. Mitochondrial Glutathione: Regulation and
537 Functions. *Antioxid. Redox. Signal.* 27, 1162-1177.
- 538 Chen, C., Jiang, X., Gu, S., Lai, Y., Liu, Y., Zhang, Z., 2017. Protection of Nrf2 against arsenite-
539 induced oxidative damage is regulated by the cyclic guanosine monophosphate-protein
540 kinase G signaling pathway. *Environ. Toxicol.* 32, 2004-2020.
- 541 Choudhury, S., Ghosh, S., Mukherjee, S., Gupta, P., Bhattacharya, S., Adhikary, A.,
542 Chattopadhyay, S., 2016. Pomegranate protects against arsenic-induced p53-dependent
543 ROS-mediated inflammation and apoptosis in liver cells. *J. Nutr. Biochem.* 38, 25-40.
- 544 Degli Esposti, M., 1998. Inhibitors of NADH-ubiquinone reductase: an overview. *Biochim.*
545 *Biophys. Acta* 1364, 222-235.

546 Ellinsworth, D.C., 2015. Arsenic, reactive oxygen, and endothelial dysfunction. *J. Pharmacol.*
547 *Exp. Ther.* 353, 458-464.

548 Ellman, G.L., 1959. Tissue sulfhydryl groups. *Arch. Biochem. Biophys.* 82, 70-77.

549 Fiandalo, M.V., Kyprianou, N., 2012. Caspase control: protagonists of cancer cell apoptosis. *Exp.*
550 *Oncol.* 34, 165-175.

551 Fiorani, M., Azzolini, C., Cerioni, L., Scotti, M., Guidarelli, A., Ciacci, C., Cantoni, O., 2015a.
552 The mitochondrial transporter of ascorbic acid functions with high affinity in the presence
553 of low millimolar concentrations of sodium and in the absence of calcium and magnesium.
554 *Biochim. Biophys. Acta* 1848, 1393-1401.

555 Fiorani, M., Azzolini, C., Guidarelli, A., Cerioni, L., Scotti, M., Cantoni, O., 2015b. Intracellular
556 dehydroascorbic acid inhibits SVCT2-dependent transport of ascorbic acid in
557 mitochondria. *Pharmacol. Res.* 99, 289-295.

558 Flora, S.J., 2011. Arsenic-induced oxidative stress and its reversibility. *Free Radic. Biol. Med.* 51,
559 257-281.

560 Forman, H.J., 2016. Redox signaling: An evolution from free radicals to aging. *Free Radic. Biol.*
561 *Med.* 97, 398-407.

562 Franklin, C.C., Backos, D.S., Mohar, I., White, C.C., Forman, H.J., Kavanagh, T.J., 2009.
563 Structure, function, and post-translational regulation of the catalytic and modifier subunits
564 of glutamate cysteine ligase. *Mol. Aspects Med.* 30, 86-98.

565 Gomes, A., Fernandes, E., Lima, J.L., 2005. Fluorescence probes used for detection of reactive
566 oxygen species. *J. Biochem. Biophys. Methods* 65, 45-80.

567 Gong, X., Ivanov, V.N., Hei, T.K., 2016. 2,3,5,6-Tetramethylpyrazine (TMP) down-regulated
568 arsenic-induced heme oxygenase-1 and ARS2 expression by inhibiting Nrf2, NF-kappaB,
569 AP-1 and MAPK pathways in human proximal tubular cells. *Arch. Toxicol.* 90, 2187-
570 2200.

571 Griffith, O.W., Mulcahy, R.T., 1999. The enzymes of glutathione synthesis: gamma-
572 glutamylcysteine synthetase. *Adv. Enzymol. Relat. Areas Mol. Biol.* 73, 209-267.

573 Guidarelli, A., Carloni, S., Balduini, W., Fiorani, M., Cantoni, O., 2016a. Mitochondrial ascorbic
574 acid prevents mitochondrial O₂⁻ formation, an event critical for U937 cell apoptosis
575 induced by arsenite through both autophagic-dependent and independent mechanisms.
576 *Biofactors* 42, 190-200.

577 Guidarelli, A., Cerioni, L., Tommasini, I., Fiorani, M., Brune, B., Cantoni, O., 2005. Role of Bcl-2
578 in the arachidonate-mediated survival signaling preventing mitochondrial permeability
579 transition-dependent U937 cell necrosis induced by peroxynitrite. *Free Radic. Biol. Med.*
580 39, 1638-1649.

581 Guidarelli, A., Fiorani, M., Azzolini, C., Cerioni, L., Scotti, M., Cantoni, O., 2015. U937 cell
582 apoptosis induced by arsenite is prevented by low concentrations of mitochondrial ascorbic
583 acid with hardly any effect mediated by the cytosolic fraction of the vitamin. *Biofactors*
584 41, 101-110.

585 Guidarelli, A., Fiorani, M., Carloni, S., Cerioni, L., Balduini, W., Cantoni, O., 2016b. The study of
586 the mechanism of arsenite toxicity in respiration-deficient cells reveals that NADPH
587 oxidase-derived superoxide promotes the same downstream events mediated by
588 mitochondrial superoxide in respiration-proficient cells. *Toxicol. Appl. Pharmacol.* 307,
589 35-44.

590 Guidarelli, A., Fiorani, M., Cerioni, L., Scotti, M., Cantoni, O., 2017. Arsenite induces DNA
591 damage via mitochondrial ROS and induction of mitochondrial permeability transition.
592 *Biofactors* 43, 673-684.

593 Hamanaka, R.B., Chandel, N.S., 2010. Mitochondrial reactive oxygen species regulate cellular
594 signaling and dictate biological outcomes. *Trends Biochem. Sci.* 35, 505-513.

595 He, X., Ma, Q., 2009. NRF2 cysteine residues are critical for oxidant/electrophile-sensing, Kelch-
596 like ECH-associated protein-1-dependent ubiquitination-proteasomal degradation, and
597 transcription activation. *Mol. Pharmacol.* 76, 1265-1278.

598 He, X., Ma, Q., 2010. Critical cysteine residues of Kelch-like ECH-associated protein 1 in arsenic
599 sensing and suppression of nuclear factor erythroid 2-related factor 2. *J. Pharmacol. Exp.*
600 *Ther.* 332, 66-75.

601 Hou, Y., Wang, Y., Wang, H., Xu, Y., 2014. Induction of glutathione synthesis in human
602 hepatocytes by acute and chronic arsenic exposure: differential roles of mitogen-activated
603 protein kinases. *Toxicology* 325, 96-106.

604 Hourihan, J.M., Moronetti Mazzeo, L.E., Fernandez-Cardenas, L.P., Blackwell, T.K., 2016.
605 Cysteine Sulfenylation Directs IRE-1 to Activate the SKN-1/Nrf2 Antioxidant Response.
606 *Mol. Cell.* 63, 553-566.

607 Jiang, T., Huang, Z., Chan, J.Y., Zhang, D.D., 2009. Nrf2 protects against As(III)-induced damage
608 in mouse liver and bladder. *Toxicol. Appl. Pharmacol.* 240, 8-14.

609 Jomova, K., Jenisova, Z., Feszterova, M., Baros, S., Liska, J., Hudecova, D., Rhodes, C.J., Valko,
610 M., 2011. Arsenic: toxicity, oxidative stress and human disease. *J. Appl. Toxicol.* 31, 95-
611 107.

612 Kooy, N.W., Royall, J.A., Ischiropoulos, H., Beckman, J.S., 1994. Peroxynitrite-mediated
613 oxidation of dihydrorhodamine 123. *Free Radic. Biol. Med.* 16, 149-156.

614 Kudryavtseva, A.V., Krasnov, G.S., Dmitriev, A.A., Alekseev, B.Y., Kardymon, O.L.,
615 Sadritdinova, A.F., Fedorova, M.S., Pokrovsky, A.V., Melnikova, N.V., Kaprin, A.D.,
616 Moskalev, A.A., Snezhkina, A.V., 2016. Mitochondrial dysfunction and oxidative stress in
617 aging and cancer. *Oncotarget* 7, 44879-44905.

618 Kurokawa, M., Kornbluth, S., 2009. Caspases and kinases in a death grip. *Cell* 138, 838-854.

619 Lau, A., Whitman, S.A., Jaramillo, M.C., Zhang, D.D., 2013. Arsenic-mediated activation of the
620 Nrf2-Keap1 antioxidant pathway. *J. Biochem. Mol. Toxicol.* 27, 99-105.

621 Leslie, E.M., 2012. Arsenic-glutathione conjugate transport by the human multidrug resistance
622 proteins (MRPs/ABCCs). *J. Inorg. Biochem.* 108, 141-149.

623 Li, B., Li, X., Zhu, B., Zhang, X., Wang, Y., Xu, Y., Wang, H., Hou, Y., Zheng, Q., Sun, G.,
624 2013. Sodium arsenite induced reactive oxygen species generation, nuclear factor
625 (erythroid-2 related) factor 2 activation, heme oxygenase-1 expression, and glutathione
626 elevation in Chang human hepatocytes. *Environ. Toxicol.* 28, 401-410.

627 Li, Y.N., Xi, M.M., Guo, Y., Hai, C.X., Yang, W.L., Qin, X.J., 2014. NADPH oxidase-
628 mitochondria axis-derived ROS mediate arsenite-induced HIF-1 α stabilization by
629 inhibiting prolyl hydroxylases activity. *Toxicol. Lett.* 224, 165-174.

630 Liu, S.X., Davidson, M.M., Tang, X., Walker, W.F., Athar, M., Ivanov, V., Hei, T.K., 2005.
631 Mitochondrial damage mediates genotoxicity of arsenic in mammalian cells. *Cancer Res.*
632 65, 3236-3242.

633 Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., 1951. Protein measurement with the
634 Folin phenol reagent. *J. Biol. Chem.* 193, 265-275.

635 Mandal, P., 2017. Molecular insight of arsenic-induced carcinogenesis and its prevention. *Naunyn*
636 *Schmiedebergs Arch. Pharmacol.* 390, 443-455.

637 Meister, A., Anderson, M.E., 1983. Glutathione. *Annu. Rev. Biochem.* 52, 711-760.

638 Pi, J., Qu, W., Reece, J.M., Kumagai, Y., Waalkes, M.P., 2003. Transcription factor Nrf2
639 activation by inorganic arsenic in cultured keratinocytes: involvement of hydrogen
640 peroxide. *Exp. Cell Res.* 290, 234-245.

641 Rao, C.V., Pal, S., Mohammed, A., Farooqui, M., Doescher, M.P., Asch, A.S., Yamada, H.Y.,
642 2017. Biological effects and epidemiological consequences of arsenic exposure, and
643 reagents that can ameliorate arsenic damage in vivo. *Oncotarget* 8, 57605-57621.

644 Ray, P.D., Huang, B.W., Tsuji, Y., 2015. Coordinated regulation of Nrf2 and histone H3 serine 10
645 phosphorylation in arsenite-activated transcription of the human heme oxygenase-1 gene.
646 *Biochim. Biophys. Acta* 1849, 1277-1288.

647 Ribas, V., Garcia-Ruiz, C., Fernandez-Checa, J.C., 2014. Glutathione and mitochondria. *Front.*
648 *Pharmacol.* 5, 151.

649 Rossler, O.G., Thiel, G., 2017. Specificity of Stress-Responsive Transcription Factors Nrf2,
650 ATF4, and AP-1. *J. Cell. Biochem.* 118, 127-140.

651 Shen, S., Li, X.F., Cullen, W.R., Weinfeld, M., Le, X.C., 2013. Arsenic binding to proteins.
652 *Chem. Rev.* 113, 7769-7792.

653 Smith, K.R., Klei, L.R., Barchowsky, A., 2001. Arsenite stimulates plasma membrane NADPH
654 oxidase in vascular endothelial cells. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 280, L442-
655 449.

656 Son, Y.O., Pratheeshkumar, P., Roy, R.V., Hitron, J.A., Wang, L., Divya, S.P., Xu, M., Luo, J.,
657 Chen, G., Zhang, Z., Shi, X., 2015. Antioncogenic and Oncogenic Properties of Nrf2 in
658 Arsenic-induced Carcinogenesis. *J. Biol. Chem.* 290, 27090-27100.

659 Straub, A.C., Clark, K.A., Ross, M.A., Chandra, A.G., Li, S., Gao, X., Pagano, P.J., Stolz, D.B.,
660 Barchowsky, A., 2008. Arsenic-stimulated liver sinusoidal capillarization in mice requires
661 NADPH oxidase-generated superoxide. *J. Clin. Invest.* 118, 3980-3989.

662 Tebay, L.E., Robertson, H., Durant, S.T., Vitale, S.R., Penning, T.M., Dinkova-Kostova, A.T.,
663 Hayes, J.D., 2015. Mechanisms of activation of the transcription factor Nrf2 by redox
664 stressors, nutrient cues, and energy status and the pathways through which it attenuates
665 degenerative disease. *Free Radic. Biol. Med.* 88, 108-146.

666 Wang, X.J., Sun, Z., Chen, W., Eblin, K.E., Gandolfi, J.A., Zhang, D.D., 2007. Nrf2 protects
667 human bladder urothelial cells from arsenite and monomethylarsonous acid toxicity.
668 *Toxicol. Appl. Pharmacol.* 225, 206-213.


669 Watanabe, T., Hirano, S., 2013. Metabolism of arsenic and its toxicological relevance. *Arch.*
670 *Toxicol.* 87, 969-979.

671 Yang, B., Fu, J., Zheng, H., Xue, P., Yarborough, K., Woods, C.G., Hou, Y., Zhang, Q.,
672 Andersen, M.E., Pi, J., 2012. Deficiency in the nuclear factor E2-related factor 2 renders


673 pancreatic beta-cells vulnerable to arsenic-induced cell damage. *Toxicol. Appl. Pharmacol.*
674 264, 315-323.

675 Yang, X., Wang, D., Ma, Y., Xu, X., Zhu, Z., Wang, X., Deng, H., Li, C., Chen, M., Tong, J.,
676 Yamanaka, K., An, Y., 2015. Continuous activation of Nrf2 and its target antioxidant
677 enzymes leads to arsenite-induced malignant transformation of human bronchial epithelial
678 cells. *Toxicol. Appl. Pharmacol.* 289, 231-239.

679
680



685 **Fig. 1.** Arsenite promotes a time-dependent expression of Nrf2 and CGLC accompanied by
 686 increased GSH biosynthesis. (A) Cells were exposed for increasing time intervals to 2.5 μ M
 687 arsenite and analysed for Nrf2 and GCLC expression using actin as a loading control. (B)
 688 Representative images providing evidence of Nrf2 expression/nuclear localization in cells
 689 exposed for 6 h to arsenite. Immunofluorescence staining indicative of Nrf2 expression in cells
 690 exposed to the vehicle (a) or to arsenite (b). (c) and (d) are images taken from the same field in
 691 which the nuclear compartments are identified by Hoechst staining. Scale bar represents 20 μ m.
 692 (C) Cells were exposed for increasing time-intervals to arsenite and then analysed for their GSH
 693 content by HPLC. (D) Cells exposed for 16 h to arsenite were analysed for their total, protein
 694 and non protein thiol content, as detailed under Materials and methods. Results represent the
 695 means \pm SD calculated from at least 3 separate experiments. *P < 0.05, **P < 0.01, as compared
 696 to untreated cells (one-way ANOVA followed by Dunnet's test).
 697



698

699 **Fig. 2.** Mitochondrial superoxide mediates the arsenite-dependent Nrf2/GCLC/GSH response.
 700 (A) Cells were exposed for increasing time intervals to 2.5 μ M arsenite, either alone or
 701 associated with 0.5 μ M rotenone (Rot) or 10 μ M AA and analysed for their DHR-fluorescence
 702 response. The effect of arsenite was also investigated in RD cells. Results represent the means \pm
 703 SD calculated from at least 3 separate experiments. * $P < 0.05$, ** $P < 0.01$, as compared to
 704 untreated cells (two-way ANOVA followed by Bonferroni's test).
 705 (B) Cells were exposed for 6h to 2.5 μ M arsenite, either alone or associated with rotenone (Rot)
 706 or AA, and analysed for Nrf2 and GCLC expression.
 707 (C) Cells were exposed for 16h to 2.5 μ M arsenite, either alone or associated with rotenone
 708 (Rot) or AA, and analysed for their GSH content. The effect of arsenite was also tested in RD
 709 cells. GSH content is expressed as a percentage of the GSH concentration found in the control
 710 cells. Results represent the means \pm SD calculated from at least 3 separate experiments. ** $P <$
 711 0.01, as compared to untreated cells (one-way ANOVA followed by Dunnet's test).






Fig. 3. The enhanced GSH biosynthesis reduces the rate of mitochondrial superoxide formation induced by arsenite. (A and B) Cells were exposed for increasing time intervals to 0 or 2.5 μM arsenite, both in the absence or presence of 2.5 μM BSO. At the indicated times, aliquots of the cells were processed for the measurement of their GSH content (results are expressed as a percentage of the GSH content of their appropriate controls, A) and for the analysis of the DHR-fluorescence response (B). Results represent the means \pm SD calculated from at least 3 separate experiments. * $P < 0.05$, ** $P < 0.01$, as compared to untreated cells or arsenite treated cells (two-way ANOVA followed by Bonferroni's test). (C) Cells were treated for 8 or 16 h with arsenite and BSO, both in the absence or presence of rotenone (Rot), AA, DPI (1 μM) or Apo (10 μM). After treatments, the cells were analyzed for DHR-fluorescence. The effect of arsenite/BSO was also tested in RD cells. (D) Representative micrographs showing p47phox localization in cells exposed for 16 h to BSO alone (a) or associated with arsenite (b). In other experiments the cells were exposed for 30 min to 100 $\mu\text{g}/\text{ml}$ PMA alone (c) or associated with Apo (d), or DPI (e). The inhibitors were added to the cultures 15 min prior to PMA treatment. The micrographs are representative of at least three separate experiments. Scale bar represents 20 μm . Panel (f) shows the DHR-fluorescence response detected in cells exposed to PMA in the absence or presence of Apo, or DPI. Results represent the means \pm SD calculated from at least 3 separate experiments. * $P < 0.05$, ** $P < 0.01$, as compared to untreated cells (one-way ANOVA followed by Dunnet's test).



733
 734 **Fig. 4.** The increased GSH biosynthesis mitigates and delays mitochondrial dysfunction induced
 735 by arsenite. (A) Cells were exposed for increasing time intervals to arsenite alone or associated
 736 with BSO. After treatments, the cells were analyzed for MitoTracker red CMXRos-fluorescence.
 737 Results represent the means \pm SD calculated from at least 3 separate experiments. * $P < 0.05$, as
 738 compared to arsenite treated cells (two-way ANOVA followed by Bonferroni's test). (B) Cells
 739 were exposed for 16 h to arsenite and BSO in the absence or presence of rotenone (Rot), AA, or
 740 CsA (0.5 μ M). Selected experiments were performed using RD cells. After treatments, the cells
 741 were analyzed for MitoTracker red CMXRos-fluorescence. Results represent the means \pm SD
 742 calculated from at least 3 separate experiments. ** $P < 0.01$, as compared to untreated cells (one-
 743 way ANOVA followed by Dunnet's test). (C) Cells were exposed for 6 h to arsenite alone, or
 744 associated with BSO, both in absence or presence of rotenone (Rot), AA, or CsA. The effect of
 745 arsenite/BSO was also tested in RD cells. After treatments, cytochrome c localization was
 746 determined by immunofluorescence staining with anti-FITC antibody. The graph shows the
 747 percentage of cells with diffused fluorescence as a consequence of the mitochondrial loss of
 748 cytochrome c (n=150). ** $P < 0.01$, as compared to untreated cells (one-way ANOVA followed
 749 by Dunnet's test).



751

752

753

754

755

Fig. 5. The increased GSH biosynthesis mitigates and delays the apoptotic death induced by

arsenite. (A) Cells were exposed for 6 or 16 h to arsenite alone, or associated with BSO, both in

absence or presence of rotenone (Rot), AA, or CsA. The effect of arsenite/BSO was also tested

in RD cells. After treatments, the cells were analysed for caspase-3 activity, as detailed in

Materials and methods. Results represent the means \pm SD calculated from at least 3 separate

experiments. * $P < 0.05$, ** $P < 0.01$, as compared to untreated cells (one-way ANOVA followed

by Dunnet's test). (B) Cells were exposed for increasing time intervals to arsenite alone or

associated with BSO. After treatments, the cells were analyzed for apoptosis, by measuring

chromatin fragmentation/condensation with the Hoechst assay. Results represent the means \pm

SD calculated from at least 3 separate experiments. * $P < 0.05$, as compared to arsenite treated

cells (two-way ANOVA followed by Bonferroni's test). The inset shows the effect of CsA,

rotenone (Rot), AA or the respiration-deficient phenotype on the apoptotic response mediated by

a 16 h exposure to arsenite/BSO. Results represent the means \pm SD calculated from at least 3

separate experiments. ** $P < 0.01$, as compared to cells exposed to arsenite/BSO (one-way

ANOVA followed by Dunnet's test). Cells were exposed for 16 h to increasing concentrations

of BSO in the absence or presence of arsenite and analysed for (C) GSH content (expressed as a

percentage of the GSH concentration found in the control cells) and for (D) apoptotic DNA

fragmentation/condensation. Results represent the means \pm SD calculated from at least 3

separate experiments. * $P < 0.05$, ** $P < 0.01$, as compared to untreated cells (two-way ANOVA

followed by Bonferroni's test).

754

755

756

757

758

759

760